Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Everolimus + Metformin|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Everolimus||Afinitor||RAD001|Zortress||mTORC1 Inhibitor 8||Afinitor (everolimus) binds to FKBP-12 and allosterically inhibits mTOR, leading to decreased mTORC1 signaling and potentially resulting in decreased tumor cell growth (PMID: 17766661, PMID: 28400999). Afinitor (everolimus) is FDA approved for use in neuroendocrine tumors of pancreatic, lung or gastrointestinal tract origin, advanced renal cell carcinoma, in adult and pediatric patients aged 1 year and older with tuberous sclerosis complex who have subependymal giant cell astrocytoma, and in combination with Aromasin (exemestane) in hormone receptor-positive, HER2-negative breast cancer (FDA.gov).|
|Metformin||Glucophage||Apo-Metformin||mTOR Inhibitor 51||Glucophage (metformin) inhibits part of the mitochondrial respiratory chain and may exert antineoplastic effects through inhibition of mTOR and is FDA approved for type 2 diabetes (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||breast cancer||not applicable||Everolimus + Metformin||Preclinical - Cell line xenograft||Actionable||In a preclinical study, the combination of Afinitor (everolimus) and Glucophage (metformin) resulted in a synergistic effect in breast cancer cells, resulting in both greater inhibition of cell growth in culture and decreased tumor growth in cell line xenograft models when compared to either agent alone (PMID: 26351208).||26351208|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|